<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461719</url>
  </required_header>
  <id_info>
    <org_study_id>TJCS_P3</org_study_id>
    <nct_id>NCT02461719</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes</brief_title>
  <official_title>Multicenter, Randomized, Double-blind phâ…¢ Study of TJCS Eye Drops Group and Restasis Eye Drops Group for 12 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taejoon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taejoon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical Study is TJCS Eye Drops 0.05%(Cyclosporine ophthalmic
      nano-emulsion) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group
      12 weeks after treatment, each treatment group comparisons for evaluation of efficacy and
      safety in Moderate to Severe Dry Eye Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>4, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal and Conjunctival staining sum Score</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease index (OSDI)</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear break up time (TBUT)</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-anesthetic Schirmer test</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of concurrent drug use</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>CYPORIN N EYE DROPS 0.05%(TJCS eye drop)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYPORIN N EYE DROPS 0.05%(TJCS eye drop) 1 drop twice/day for 12 weeks to both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis eye drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYPORIN N EYE DROPS 0.05%(TJCS eye drop)</intervention_name>
    <description>1 drop twice/day for 12 weeks to both eyes.</description>
    <arm_group_label>CYPORIN N EYE DROPS 0.05%(TJCS eye drop)</arm_group_label>
    <other_name>Cyclosporine Eye Drops(CYPORIN N)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis</intervention_name>
    <description>1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.</description>
    <arm_group_label>Restasis eye drop</arm_group_label>
    <other_name>Cyclosporine Eye Drops (Restasis)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 20 or over

          -  Patients with moderate to severe dry eye

          -  Screening both eyes, the corrected visual acuity is 0.2 or more

        Exclusion Criteria:

          -  Screening visits within 4 weeks who treated with systemic cyclosporine or topical
             cyclosporine ophthalmic solutions.

          -  Screening visits within 2 months the patients with systemic or ocular disorders
             affected the test results (ocular surgery, trauma, or disease)

          -  Intraocular pressure(IOP)&gt; 25 mmHg

          -  Patient using or to use punctual plug within 1 months.

          -  Patients with contact lens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 8, 2015</submitted>
    <returned>June 15, 2015</returned>
    <submitted>June 22, 2015</submitted>
    <returned>July 21, 2015</returned>
    <submitted>July 21, 2015</submitted>
    <returned>August 17, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

